
Design Therapeutics Investor Relations Material
Latest events

Q4 2023
Design Therapeutics

Q1 2025
26 Jun, 2025

Q4 2024
10 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Design Therapeutics Inc
Access all reports
Design Therapeutics Inc. is a preclinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nucleotide repeat expansions. Their innovative approach centers on the development of GeneTAC™ gene targeted chimera small molecules. These molecules are designed to modulate the expression of disease-causing genes, offering potential treatments for a range of genetic disorders. The company's research portfolio includes projects targeting conditions such as Friedreich Ataxia, a severe progressive multi-system disease; Myotonic Dystrophy Type-1 (DM1), affecting muscle, heart, and other organs; and other nucleotide repeat expansion-driven diseases like Fragile X syndrome and Huntington disease. The company is headquartered in Carlsbad, California, and its shares are listed on the Nasdaq.
Latest articles
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
Ticker symbol
DSGN
Country
🇺🇸 United States